Stride Green, Khari Foods, and The Tarzan Way Raise Early-Stage Funding
The Indian brands have announced their latest investment rounds.
You're reading Entrepreneur India, an international franchise of Entrepreneur Media.
Stride Green Raises USD 3.5 Mn Funding Led by Micelio
Stride Green has raised USD 3.5 million in a seed round led by Micelio Technology Fund and Incubate Fund Asia, along with other strategic investors.
The funding will be deployed to scale its tech-enabled asset financing and lifecycle management solutions for India's clean energy sectors, including electric mobility, battery storage, and renewable energy. It will also be used to expand the team and deepen technological capabilities.
Founded by Ishpreet Gandhi and Vivek Jain, Stride Green is a climate-tech platform offering end-to-end leasing, financing, and lifecycle management services for sustainable businesses. Its proprietary technology stack provides real-time analytics, operational alerts, and insights that enhance asset performance and longevity.
Currently, the Gurugram-based platform manages over 3,000 cleantech assets and partners with OEMs and logistics companies.
"At Stride Green, we're driven by deep domain expertise and a clear purpose to develop innovative and scalable solutions for the climate-tech ecosystem," said Vivek Jain, Co-Founder and CEO. "With mission-aligned partners like Micelio and Incubate, we are empowered to deliver high-impact solutions for a more sustainable future."
Stride Green now aims for vertical and geographic expansion, positioning itself as a critical enabler in India's green economy transition.
Khari Foods Secures INR 3 Cr from Meri Punji IMF
Grahill Wellness, the parent company of Delhi-based clean-label brand Khari Foods has raised INR 3 crore in a seed round led by Meri Punji IMF Private Limited to scale its healthy snacking footprint nationwide.
The funds will be deployed toward product innovation, team expansion, R&D, and strengthening marketing and distribution across tier I and tier II cities.
Founded in 2022 by Yash (Co-Founder and CEO) and Sunil Bansal (Co-Founder and COO), Khari Foods offers palm oil-free, maida-free snacks enriched with fibre and micronutrients. Its diverse product line includes Ragi Crispies, Beetroot Crispies, Jowar Puffs, Snack Mixes, and Dates-based sweets—designed for health-conscious consumers aged 20–40 in urban and semi-urban markets.
"From day one, our focus has been on building a brand that delivers nutritious, flavourful snacks made for Indian tastes, without cutting corners," said Yash. "This INR 3 crore fundraise marks a pivotal moment for us, enabling faster growth and exciting new launches."
Backed by a state-of-the-art facility in Haryana, Khari Foods stands out with proprietary formulations and end-to-end supply chain control. The brand is projecting a 208% jump in annual revenue run rate this year, underlining its momentum in India's evolving healthy snacking segment.
The Tarzan Way Bags INR 2 Cr from Inflection Point Ventures and more
Noida-based AI-powered travel tech startup The Tarzan Way has secured INR 2 crore in seed funding, led by Inflection Point Ventures, with additional backing from Your Trips Limited (UK), Prateek Maheshwari (Founder, PhysicsWallah), and other angel investors.
The funds will be allocated towards product development (35%), operations (25%), marketing (20%), HR (15%), and miscellaneous needs (5%), including the launch of the startup's upcoming "Exploration App."
Founded in 2020 by Shikhar Chadha and Shivank Tripathi, The Tarzan Way empowers users to design hyper-personalised, authentic holidays in seconds using AI. The platform combines deep tech with a storytelling approach to deliver immersive itineraries, a smart booking engine, 24/7 live concierge, and one-click travel planning.
"Our passion lies in creating memories that last. We don't just plan trips; we help people craft stories that stay with them forever," said Shikhar Chadha, Co-founder.
Ankur Mittal, Co-founder of Inflection Point Ventures, added, "Tarzan Way bridges the gap between rigid travel plans and chaotic self-planning, offering travellers smart, tailored experiences."
With 300% YoY revenue growth, 70% MoM user growth, and INR 13.5 Cr in gross bookings, The Tarzan Way is quickly establishing itself as a global leader in experiential, tech-driven travel.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Stock market today: Dow, S&P 500 and Nasdaq futures rise with stocks set to end June with a bang
US stock futures edged higher on Monday, setting up the major indexes for more records to end one of the most volatile first halves of a year in recent memory. Dow Jones Industrial Average futures (YM=F) rose around 0.5%. Contracts on the S&P 500 (ES=F) gained 0.3%, while those on the tech-heavy Nasdaq 100 (NQ=F) added roughly 0.5%. Several of Trump's economic agenda items are in focus this week. A July 9 deadline looms before the possible resumption of Trump's unilateral tariffs, which Trump on Sunday said he didn't think he'd "need to" extend. On the trade front, India has extended its Washington visit to finalize a deal. Administration officials last week confirmed a trade framework with China was in place, bolstering investor sentiment despite a late-Friday dip triggered by Trump's abrupt halt to talks with Canada, citing its digital tax policy. Canada scrapped its digital services tax targeting US technology firms late on Sunday, just hours before it was due to take effect, in a bid to advance stalled trade negotiations. Meanwhile, market watchers are closely following Senate negotiations over Trump's proposed $4.5 trillion tax cut bill. The Congressional Budget Office estimates it would add $3.3 trillion to the deficit over a decade. For the market, June's gains have been substantial, fueled by optimism surrounding global trade and easing fears over tariffs. The S&P 500 (^GSPC) is up over 4%, the Nasdaq Composite (^IXIC) has surged over 5.5%, and the Dow (^DJI) has climbed 3.5%. On Friday, all three major indexes closed higher, with the S&P 500 and Nasdaq reaching new record highs for the first time since February — the start of the year's tariff-fueled stock swings. All three major indexes are up at least 3% so far this year. Oil prices fell overnight Sunday as global markets adjusted to the easing of tensions in the Middle East, in combination with a commitment from OPEC+ to increase supply in August. Reuters reports: Read more here. Oil prices fell overnight Sunday as global markets adjusted to the easing of tensions in the Middle East, in combination with a commitment from OPEC+ to increase supply in August. Reuters reports: Read more here. Sign in to access your portfolio
Associated Press
an hour ago
- Associated Press
CHC Navigation Introduces CoCloud: A Cloud-Based Platform for Efficient 3D Data Processing and Collaboration
CHCNAV launched CoCloud, a cloud-native platform for 3D data processing, enhancing collaboration and reducing hardware needs for geospatial professionals. SHANGHAI, CHINA, June 30, 2025 / / -- CHC Navigation (CHCNAV), a global provider of geospatial solutions, today announced the launch of CoCloud, a comprehensive cloud-native platform designed for 3D data processing, management, and collaborative analysis. CoCloud offers robust tools for handling multi-source 3D data, facilitating streamlined workflows from data acquisition to deliverable creation without requiring local hardware investment. Simon Wu, Director of Geospatial Software at CHC Navigation, commented, 'CoCloud represents a significant advancement in how professionals handle 3D spatial data. By moving complex processing operations to the cloud, we've created a solution that not only reduces hardware requirements but also streamlines workflows and enhances team collaboration across multiple projects and locations.' Powerful Cloud Processing Engine CoCloud features an advanced photogrammetry engine that efficiently processes multi-source data including aerial imagery and LiDAR scans. The platform generates high-quality digital orthophotos, point clouds, and OSGB models with professional-grade precision. Streamlined Collaboration and Workflow Designed to foster teamwork, CoCloud provides tools for online data visualization, sharing, and real-time collaboration on tasks like volume calculations and point cloud editing. Its intuitive, user-friendly interface makes sophisticated 3D data operations accessible without extensive specialized training, supporting efficient project execution. The platform supports various data formats and offers functionalities like dataset and timeline management. Flexible Integration Options CoCloud is built for adaptability, offering API access and private deployment options. This flexibility allows for integration into existing client systems and supports customized workflows, from initial data collection through to final application delivery, ensuring that organizations can tailor the platform to their specific operational requirements. Distributed data centers Our distributed data center infrastructure in Germany and Ireland enables localized storage and processing of user data. Both facilities strictly comply with the EU's General Data Protection Regulation (GDPR), ensuring full lifecycle compliance from data collection and transmission to storage. About CHC Navigation CHC Navigation (CHCNAV) develops advanced mapping, navigation and positioning solutions designed to increase productivity and efficiency. Serving industries such as geospatial, agriculture, construction and autonomy, CHCNAV delivers innovative technologies that empower professionals and drive industry advancement. With a global presence spanning over 140 countries and a team of more than 2,000 professionals, CHC Navigation is recognized as a leader in the geospatial industry and beyond. For more information about CHC Navigation [Huace: please visit: Xu Can CHC Navigation [email protected] Visit us on social media: LinkedIn Instagram Facebook YouTube Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Associated Press
an hour ago
- Associated Press
Piramal Pharma Solutions Breaks Ground on $90M Expansion Plan
MUMBAI, India, June 30, 2025 /CNW/ -- Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), recently announced a $90M investment plan to expand two of its U.S. facilities, which are critical to its integrated offering. This ambitious investment underscores the company's commitment to industry leadership through continuous growth and innovation. The two sites involved in the expansion are: Piramal Pharma recently broke ground on the expansion plan for its Lexington, Kentucky facility. To celebrate this important milestone and the future growth it signifies for the company, Piramal Pharma hosted a groundbreaking ceremony at the facility on June 25, 2025. This investment comes at a pivotal moment for the sterile injectables market, which is experiencing significant growth driven by increased medical necessity, broader regulatory approvals, and sizable advancements in scientific research and development. Additionally, the streamlined delivery systems associated with sterile injectables contribute to their efficacy and safety, making these solutions increasingly popular among both healthcare providers and patients. Similarly, ADC therapies are gaining substantial traction, fueled by ongoing innovation, wider regulatory acceptance, and robust evidence demonstrating their effectiveness. The growing prevalence of ADCs underscores the pressing need for expanded manufacturing and development capabilities to meet the evolving landscape of patient care. This investment positions Piramal Pharma to capitalize on these trends, ensuring the company can meet the rising demand for both sterile injectables and ADC therapies while enhancing its competitive edge in the market. Upon completion of the expansion in late 2027, the Lexington site will more than double its manufacturing capacity, increasing from 104 product batches per year (at peak utilization) to over 240 annual batches. 'We prioritize patient, consumer, and customer centricity in all our operations, engaging with the populations we serve to better understand, anticipate, and address their needs. Our research has revealed that the sterile injectables market is projected to exceed $20B by 2028, underscoring the urgent need for us to enhance our offerings in this segment. We are confident that this strategic $90M investment will empower us to meet the demands of this market, reinforcing our position as a trusted global partner in biologic manufacturing. By enhancing the services we provide to our partners, we can reduce the burden of disease for more patients around the globe,' said Nandini Piramal, Chairperson, Piramal Pharma. 'As the market adjusts and preferences shift, we are committed to adapting to meet its current requirements,' said Peter DeYoung, Chief Executive Officer, Piramal Global Pharma. 'ADCs are rapidly emerging as one of the most effective classes of precision immunotherapy targeting certain cancers and tumors. As this class of drugs becomes more prevalent, we will adapt our services to accommodate this growing demand. By investing in the Lexington and Riverview facilities, we will enhance our integrated ADC offering, ADCelerate™, and increase our capacity to bring high-quality, innovative treatments to our clients and their patients worldwide.' The Lexington facility expansion also represents an investment in the local community, creating 40 new full-time jobs that will enhance the local economy and strengthen Piramal Pharma's workforce. Piramal Pharma will continue to work alongside local partners, leveraging the region's strengths to remain at the forefront of innovation. Additionally, this investment aligns with the growing trend toward U.S. onshore manufacturing, reinforcing the company's dedication to domestic production in the U.S. and supply chain resilience. At the groundbreaking ceremony, Lexington Mayor Linda Gorton expressed her excitement about the project and the promising opportunities it presents for the city, stating, 'Piramal's decision to expand its facility here in Lexington sends a message around the world that Lexington is a great place to do business. Lexington is home to one of the nation's best pharmacy programs – the University of Kentucky College of Pharmacy – and we are well on our way to becoming a leader in the pharmaceutical industry, as well.' Others echoed Mayor Gorton's sentiment with equal enthusiasm, including Jim Stephanou, CEO of IPS-Integrated Project Services, who said, 'IPS is a proud supporter of Piramal's growth over the past five years, providing fit-for-purpose solutions on transformative projects across India, the UK, Canada, and the U.S. Our longstanding relationship is built on trust and a relentless commitment to technical excellence. Nothing is more rewarding than seeing shovels in the ground, especially here in Lexington. This groundbreaking highlights our deep expertise in Aseptic Fill/Finish facilities, and our passion to help Piramal bring this advanced manufacturing facility to life to deliver critical therapies to patients around the world.' Commerce Lexington President and CEO, Bob Quick, said, 'We are proud to celebrate this milestone moment with Piramal and excited for its continued growth and success. Biotech is a key strategic target for Greater Lexington economic development professionals, and this expansion will further strengthen the region as a hub for biotech and life sciences. Piramal's investment highlights the advantages of the area as an exceptional place where innovative companies come to grow and thrive.' Piramal Pharma Solutions' $90M investment in its U.S. facilities represents a significant advancement in its manufacturing capabilities and underscores its ongoing commitment to patient-centric care. This strategic move will enable Piramal Pharma to meet the evolving needs of the healthcare landscape, positioning the company at the forefront of the rapidly growing sterile injectables and ADC markets and ensuring a brighter future for patients and communities alike. About Piramal Pharma Solutions Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited. For more information visit: Piramal Pharma Solutions | LinkedIn | Facebook | X About Piramal Pharma Limited Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments. For more information, visit: Piramal Pharma | LinkedIn * Includes one facility via PPL's minority investment in Yapan Bio. Photo: Logo: View original content to download multimedia: SOURCE Piramal Pharma Ltd
